Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Bon Natural Life ( (BON) ) is now available.
On December 5, 2025, Bon Natural Life Limited announced a strategic collaboration with Shaanxi Qingshengyuan Health Industry Co., Ltd., marking a significant expansion in the functional health product market in China. This agreement, valued at $12 million over 24 months, allows Qingshengyuan to market and distribute BON’s kombucha-inspired tea pigment products across Greater China. The partnership is expected to enhance BON’s market presence and support the development of its tea-pigment product portfolio, aligning with the increasing consumer interest in natural ingredients and health benefits.
The most recent analyst rating on (BON) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Bon Natural Life stock, see the BON Stock Forecast page.
Spark’s Take on BON Stock
According to Spark, TipRanks’ AI Analyst, BON is a Neutral.
Bon Natural Life’s overall stock score is primarily impacted by its challenging financial performance and bearish technical indicators. While the stock appears undervalued based on its P/E ratio, significant financial and operational challenges overshadow this potential opportunity.
To see Spark’s full report on BON stock, click here.
More about Bon Natural Life
Bon Natural Life Limited (BON) is a Cayman Islands company operating in the natural, health, and personal care industries. It is recognized as a leading bio-ingredient solution provider, focusing on developing products that cater to the growing demand for natural and health-oriented consumer goods.
Average Trading Volume: 106,317
Technical Sentiment Signal: Sell
Current Market Cap: $12.86M
Learn more about BON stock on TipRanks’ Stock Analysis page.